Sanofi is currently working on reinforcing its strategic franchises which are set to drive growth into the next decade. The established products will progressively decline whereas the Diabetes/CV GBU will be highly dependent on Praluent. We see the trajectory as positive, believing that it could ultimately open the way to a new and compelling investment case. That said, it is still a tad early in our view.
For more information, please contact email@example.com